(IVZ) - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: BMG491BT1088
Stock: Mutual Funds, ETFs, Private Funds, Managed Portfolios
Total Rating 64
Risk 84
Buy Signal 0.06
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.34% |
| Yield on Cost 5y | 5.78% |
| Yield CAGR 5y | 5.86% |
| Payout Consistency | 93.6% |
| Payout Ratio | 32.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.9% |
| Relative Tail Risk | -5.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.04 |
| Alpha | 27.97 |
| Character TTM | |
|---|---|
| Beta | 1.513 |
| Beta Downside | 1.857 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.52% |
| CAGR/Max DD | 0.50 |
Description: IVZ January 06, 2026
Invesco Ltd. (NYSE:IVZ) is a global investment manager that serves a broad client base-including retail, institutional, high-net-worth, public entities, and sovereign wealth funds-through a suite of equity, fixed-income, multi-asset, and alternative strategies. The firm operates both mutual funds and ETFs, and it also manages private funds, deploying capital across public equities, bonds, commodities, and currencies, typically investing $5-$15 million per company.
As of the end of 2023, Invesco reported approximately $1.5 trillion in assets under management (AUM) and generated $6.4 billion in revenue, reflecting a 31 % operating margin. The asset-management sector is currently driven by fee compression from the shift toward low-cost passive products and heightened demand for ESG-aligned investments, which together influence net inflows and profit margins for firms like Invesco.
For a deeper quantitative assessment of Invesco’s valuation metrics, the ValueRay platform offers a concise dashboard you may find useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: -281.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.41 > 1.0 |
| NWC/Revenue: -7.19% < 20% (prev 29.32%; Δ -36.51% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.53b > Net Income -281.7m |
| Net Debt (-1.04b) to EBITDA (1.38b): -0.75 < 3 |
| Current Ratio: 0.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (453.8m) vs 12m ago -0.07% < -2% |
| Gross Margin: 43.18% > 18% (prev 0.33%; Δ 4284 % > 0.5%) |
| Asset Turnover: 23.57% > 50% (prev 22.46%; Δ 1.11% > 0%) |
| Interest Coverage Ratio: -6.63 > 6 (EBITDA TTM 1.38b / Interest Expense TTM 82.5m) |
Altman Z'' 1.53
| A: -0.02 (Total Current Assets 1.04b - Total Current Liabilities 1.50b) / Total Assets 27.09b |
| B: 0.26 (Retained Earnings 7.17b / Total Assets 27.09b) |
| C: -0.02 (EBIT TTM -546.7m / Avg Total Assets 27.05b) |
| D: 0.87 (Book Value of Equity 12.23b / Total Liabilities 14.09b) |
| Altman-Z'' Score: 1.53 = BB |
What is the price of IVZ shares?
As of February 07, 2026, the stock is trading at USD 26.82 with a total of 5,091,247 shares traded.
Over the past week, the price has changed by -1.72%, over one month by -5.06%, over three months by +15.68% and over the past year by +46.10%.
Over the past week, the price has changed by -1.72%, over one month by -5.06%, over three months by +15.68% and over the past year by +46.10%.
Is IVZ a buy, sell or hold?
has received a consensus analysts rating of 3.07.
Therefor, it is recommend to hold IVZ.
- StrongBuy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the IVZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.1 | 12.2% |
| Analysts Target Price | 30.1 | 12.2% |
| ValueRay Target Price | 29.8 | 11% |
IVZ Fundamental Data Overview January 31, 2026
P/E Forward = 10.5374
P/S = 1.9466
P/B = 1.0063
P/EG = 0.4373
Revenue TTM = 6.38b USD
EBIT TTM = -546.7m USD
EBITDA TTM = 1.38b USD
Long Term Debt = 10.79b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 1.62b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -1.04b USD (from netDebt column, last quarter)
Enterprise Value = 13.00b USD (12.41b + Debt 1.62b - CCE 1.04b)
Interest Coverage Ratio = -6.63 (Ebit TTM -546.7m / Interest Expense TTM 82.5m)
EV/FCF = 8.64x (Enterprise Value 13.00b / FCF TTM 1.51b)
FCF Yield = 11.58% (FCF TTM 1.51b / Enterprise Value 13.00b)
FCF Margin = 23.61% (FCF TTM 1.51b / Revenue TTM 6.38b)
Net Margin = -4.42% (Net Income TTM -281.7m / Revenue TTM 6.38b)
Gross Margin = 43.18% ((Revenue TTM 6.38b - Cost of Revenue TTM 3.62b) / Revenue TTM)
Gross Margin QoQ = 66.96% (prev 34.17%)
Tobins Q-Ratio = 0.48 (Enterprise Value 13.00b / Total Assets 27.09b)
Interest Expense / Debt = 1.42% (Interest Expense 23.0m / Debt 1.62b)
Taxrate = 21.0% (US default 21%)
NOPAT = -431.9m (EBIT -546.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.69 (Total Current Assets 1.04b / Total Current Liabilities 1.50b)
Debt / Equity = 0.13 (Debt 1.62b / totalStockholderEquity, last quarter 12.23b)
Debt / EBITDA = -0.75 (Net Debt -1.04b / EBITDA 1.38b)
Debt / FCF = -0.69 (Net Debt -1.04b / FCF TTM 1.51b)
Total Stockholder Equity = 13.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.04% (Net Income -281.7m / Total Assets 27.09b)
RoE = -2.06% (Net Income TTM -281.7m / Total Stockholder Equity 13.70b)
RoCE = -2.23% (EBIT -546.7m / Capital Employed (Equity 13.70b + L.T.Debt 10.79b))
RoIC = -3.50% (negative operating profit) (NOPAT -431.9m / Invested Capital 12.34b)
WACC = 10.29% (E(12.41b)/V(14.04b) * Re(11.49%) + D(1.62b)/V(14.04b) * Rd(1.42%) * (1-Tc(0.21)))
Discount Rate = 11.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
[DCF Debug] Terminal Value 74.19% ; FCFF base≈1.35b ; Y1≈1.67b ; Y5≈2.84b
Fair Price DCF = 75.90 (EV 32.66b - Net Debt -1.04b = Equity 33.70b / Shares 444.0m; r=10.29% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 42.74 | EPS CAGR: 2.75% | SUE: 0.73 | # QB: 0
Revenue Correlation: 46.64 | Revenue CAGR: 1.01% | SUE: 3.37 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.59 | Chg30d=+0.031 | Revisions Net=+6 | Analysts=9
EPS current Year (2026-12-31): EPS=2.68 | Chg30d=+0.171 | Revisions Net=+7 | Growth EPS=+32.2% | Growth Revenue=+13.2%
EPS next Year (2027-12-31): EPS=3.04 | Chg30d=+0.162 | Revisions Net=+5 | Growth EPS=+13.1% | Growth Revenue=+5.7%
P/S = 1.9466
P/B = 1.0063
P/EG = 0.4373
Revenue TTM = 6.38b USD
EBIT TTM = -546.7m USD
EBITDA TTM = 1.38b USD
Long Term Debt = 10.79b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 1.62b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -1.04b USD (from netDebt column, last quarter)
Enterprise Value = 13.00b USD (12.41b + Debt 1.62b - CCE 1.04b)
Interest Coverage Ratio = -6.63 (Ebit TTM -546.7m / Interest Expense TTM 82.5m)
EV/FCF = 8.64x (Enterprise Value 13.00b / FCF TTM 1.51b)
FCF Yield = 11.58% (FCF TTM 1.51b / Enterprise Value 13.00b)
FCF Margin = 23.61% (FCF TTM 1.51b / Revenue TTM 6.38b)
Net Margin = -4.42% (Net Income TTM -281.7m / Revenue TTM 6.38b)
Gross Margin = 43.18% ((Revenue TTM 6.38b - Cost of Revenue TTM 3.62b) / Revenue TTM)
Gross Margin QoQ = 66.96% (prev 34.17%)
Tobins Q-Ratio = 0.48 (Enterprise Value 13.00b / Total Assets 27.09b)
Interest Expense / Debt = 1.42% (Interest Expense 23.0m / Debt 1.62b)
Taxrate = 21.0% (US default 21%)
NOPAT = -431.9m (EBIT -546.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.69 (Total Current Assets 1.04b / Total Current Liabilities 1.50b)
Debt / Equity = 0.13 (Debt 1.62b / totalStockholderEquity, last quarter 12.23b)
Debt / EBITDA = -0.75 (Net Debt -1.04b / EBITDA 1.38b)
Debt / FCF = -0.69 (Net Debt -1.04b / FCF TTM 1.51b)
Total Stockholder Equity = 13.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.04% (Net Income -281.7m / Total Assets 27.09b)
RoE = -2.06% (Net Income TTM -281.7m / Total Stockholder Equity 13.70b)
RoCE = -2.23% (EBIT -546.7m / Capital Employed (Equity 13.70b + L.T.Debt 10.79b))
RoIC = -3.50% (negative operating profit) (NOPAT -431.9m / Invested Capital 12.34b)
WACC = 10.29% (E(12.41b)/V(14.04b) * Re(11.49%) + D(1.62b)/V(14.04b) * Rd(1.42%) * (1-Tc(0.21)))
Discount Rate = 11.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
[DCF Debug] Terminal Value 74.19% ; FCFF base≈1.35b ; Y1≈1.67b ; Y5≈2.84b
Fair Price DCF = 75.90 (EV 32.66b - Net Debt -1.04b = Equity 33.70b / Shares 444.0m; r=10.29% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 42.74 | EPS CAGR: 2.75% | SUE: 0.73 | # QB: 0
Revenue Correlation: 46.64 | Revenue CAGR: 1.01% | SUE: 3.37 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.59 | Chg30d=+0.031 | Revisions Net=+6 | Analysts=9
EPS current Year (2026-12-31): EPS=2.68 | Chg30d=+0.171 | Revisions Net=+7 | Growth EPS=+32.2% | Growth Revenue=+13.2%
EPS next Year (2027-12-31): EPS=3.04 | Chg30d=+0.162 | Revisions Net=+5 | Growth EPS=+13.1% | Growth Revenue=+5.7%